SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) ("Kite") a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced four presentations relating to its clinical programs will be delivered at the upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
